Study of XB010 in Subjects With Solid Tumors
Public ClinicalTrials.gov record NCT06545331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT06545331
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Exelixis
- Industry
- Enrollment
- 396 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- XB010 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2024
- Primary completion
- Nov 22, 2026
- Completion
- Oct 19, 2027
- Last update posted
- Apr 14, 2026
2024 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #4 | Irvine | California | 92618 | Recruiting |
| Exelixis Clinical Site #19 | Los Angeles | California | 90095 | Recruiting |
| Exelixis Clinical Site #10 | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Exelixis Clinical Site #18 | Orlando | Florida | 32827 | Recruiting |
| Exelixis Clinical Site #12 | Atlanta | Georgia | 30322 | Recruiting |
| Exelixis Clinical Site #15 | Chicago | Illinois | 60637 | Recruiting |
| Exelixis Clinical Site #5 | St Louis | Missouri | 63110 | Recruiting |
| Exelixis Clinical Site #3 | Huntersville | North Carolina | 28078 | Recruiting |
| Exelixis Clinical Site #6 | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Exelixis Clinical Site #9 | Nashville | Tennessee | 37203 | Recruiting |
| Exelixis Clinical Site #1 | Austin | Texas | 78758 | Recruiting |
| Exelixis Clinical Site #7 | Dallas | Texas | 74246 | Recruiting |
| Exelixis Clinical Site #8 | Houston | Texas | 77030 | Recruiting |
| Exelixis Clinical Site #11 | Fairfax | Virginia | 22031 | Recruiting |
| Exelixis Clinical Site #2 | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06545331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06545331 live on ClinicalTrials.gov.